false
OasisLMS
Catalog
SCCM Resource Library
Management of Bleeding due to Anticoagulants
Management of Bleeding due to Anticoagulants
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The presentation focuses on strategies for pharmacologic anticoagulation reversal. It highlights available anticoagulants and underscores the importance of understanding the coagulation cascade, pharmacokinetics, and pharmacodynamics for selecting appropriate reversal agents. For heparin and warfarin, agents like protamine and four-factor PCC are discussed, while specific reversal agents for newer anticoagulants, such as idaresuzumab and andexanet-alpha, are examined through studies like REVERSE-AD and INEXA-4. The presenter also explores guidelines from various medical societies, noting discrepancies in recommendations, especially concerning DOACs. The need for institutional guidelines is emphasized due to the limited and sometimes conflicting literature. Additionally, there's a spotlight on seroparentatag, a promising new agent capable of reversing multiple anticoagulants. Key takeaways include the importance of understanding anticoagulation pharmacology, evaluating limited reversal data, and considering future developments in novel agents.
Asset Caption
One-Hour Concurrent Session | All Bleeding Stops Eventually: A Review of Normal and Abnormal Coagulation
Meta Tag
Content Type
Presentation
Membership Level
Professional
Membership Level
Select
Year
2024
Keywords
anticoagulation reversal
coagulation cascade
reversal agents
DOAC guidelines
seroparentatag
×
Please select your language
1
English